Twenty-five years clinical trials of the German Hodgkin Study Group (GHSG)

European Journal of Haematology, Supplement

Volumn 75, Issue 66, 2005, Pages 21-25

  Behringer, Karolin ^a   Diehl, V ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

Chemotherapy; German Hodgkin Study Group; GHSG; Hodgkin's Lymphoma; Radiotherapy; Review

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; GASTROINTESTINAL TOXICITY; HODGKIN DISEASE; HUMAN; LEUKOPENIA; NAUSEA; PHARYNX DISEASE; PRIORITY JOURNAL; THROMBOCYTOPENIA; CASE CONTROL STUDY; EDITORIAL; FEMALE; HISTORY; MALE; META ANALYSIS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASE-CONTROL STUDIES; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HODGKIN DISEASE; HUMANS; MALE; META-ANALYSIS; MIDDLE AGED;

EID: 21044455872     PISSN: 09024506     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00450.x     Document Type: Conference Paper

References (13)

1. GOLDIE JH, COLDMAN AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
2. HASENCLEVER D, LOEFFLER M, DIEHL V. Rationale for dose escalation of first line conventional chemotherapy in advanced Hodgkin's disease. German Hodgkin's Lymphoma Study Group. Ann Oncol 1996;7(Suppl. 4):95-98.
3. DIEHL V, SIEBER M, KUFFER U, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997;8:143-148.
4. DIEHL V, PFREUNDSCHUH M, LOEFFLER M, et al. Chemotherapy of Hodgkin's lymphoma with alternating cycles of COPP (cyclophosphamide, vincristin, procarbazine, prednisone) and ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine). Results of the HD1 and HD3 trials of the German Hodgkin Study Group. Med Oncol Tumor Pharmacother 1989;6:155-162.
5. DUHMKE E, FRANKLIN J, PFREUNDSCHUH M, et al. Low-dose radiation is sufficient for the non-involved extended-field treatment in favorable early-stage Hodgkin's disease: long-term results of a randomized trial of radiotherapy alone. J Clin Oncol 2001;19:2905-2914.
6. SIEBER M, TESCH H, PFISTNER B, et al. Rapidly alternating COPP/ABV/IMEP is not superior to conventional alternating COPP/ABVD in combination with extended-field radiotherapy in intermediate-stage Hodgkin's lymphoma: final results of the German Hodgkin's lymphoma study group trial HD5. J Clin Oncol 2002;20:476-484.
7. SIEBER M, TESCH H, PFISTNER B, et al. Treatment of advanced Hodgkin's disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkin's lymphoma study group HD6 trial. Ann Oncol 2004;15:276-282.
8. SIEBER M, FRANKLIN J, TESCH H, et al. Two cycles ABVD plus extended field radiotherapy is superior to radiotherapy alone in early stage Hodgkin's disease: results of the German Hodgkin's lymphoma study group trial HD 7. Blood 2002;100:A341.
9. ENGERT A, SCHILLER P, JOSTING A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's lymphoma study group. J Clin Oncol 2003; 21:3601-3608.
10. DIEHL V, FRANKLIN J, PFREUNDSCHUH M, et al. Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. N Engl J Med 2003;348:2386-2395.
11. DIEHL V, STEIN H, HUMMEL M, et al. Optimisation of combined modality treatment intensity in early stage Hodgkin's lymphoma: interim results of the HD10 trial of the GHSG. Blood 2004;104:A1307.
12. DIEHL V, STEIN H, HUMMEL M, et al. Intensification of chemotherapy and concomitant doses reduction of radiotherapy in intermediate stage Hodgkin's lymphoma: interim results of the HD11 trial of the GHSG. Blood 2004;104:A1308.
13. DIEHL V, SCHILLER P, ENGERT A, et al. Results of the third interim analysis of the HD12 trial of the GHSG: 8 courses of escalated BEACOPP versus 4 escalated and 4 baseline courses of BEACOPP with or without additive radiotherapy for advanced stage Hodgkin's. Blood 2003;102:A85.